Singapoo - Kiingereza - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - aprotinin - injection - 500000 kiu/50 ml - aprotinin 500000 kiu/50 ml

Israeli - Kiingereza - Ministry of Health

bayer israel ltd - ethinylestradiol; gestodene - coated tablets - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - oral contraceptive.

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each tablet contains aspirin 300 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each chew tablet contains aspirin 500,0 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each effervescent tablet contains aspirin 400,0 mg vitamin c 240,0 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each tablet contains aspirin 500,0 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

bayer (pty) ltd û isando - tablet - see ingredients - each effervescent tablet contains aspirin 500,0 mg

Malta - Kiingereza - Medicines Authority

bayer healthcare ag - ascorbic acid 240 mg, acetylsalicylic acid 400 mg - effervescent tablet

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

bayer healthcare ag - pradofloxacin - antibacterials for systemic use - dogs - dogs:, infections of the skin and soft tissues, i.e. superficial and deep pyoderma and wound infections caused by gram-positive organisms, typically staphylococcus spp. and streptococcus spp., and gram-negative organisms such as escherichia coli, pseudomonas spp. and proteus spp., infections of the urinary tract caused by gram-negative bacteria such as enterobacteriaceae, e.g. escherichia coli, enterobacter spp., klebsiella spp. and proteus spp., pseudomonas spp., and gram-positive organisms, typically staphylococcus spp., infections of the gingiva and periodontal tissues caused by anaerobic organisms, for example porphyromonas spp., prevotella spp.; fusobacterium spp., eikenella spp. and capnophilic bacteria such as capnocytophaga spp., , cats:, infections of the respiratory tract caused by gram-negative organisms such as pasteurella spp., escherichia coli and pseudomonas spp., and gram-positive organisms such as streptococcus spp. and staphylococcus spp.,

Marekani - Kiingereza - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4)]. avelox is indicated in adult patients for the treatment of complicated skin and skin